Use of denosumab in recurrent chondroblastoma of the squamous temporal bone: a case report

Abstract

Chondroblastoma is a rare, benign bone tumor that represents 1–2% of all primary bone tumors. Denosumab, a monoclonal antibody, has been demonstrated to inhibit the growth of giant cell tumors. We report a case of recurrent chondroblastoma of the squamous temporal bone that is currently suppressed with denosumab.